New York Added MLD to Newborn Screening Panel
The state launched testing for metachromatic leukodystrophy to identify infants requiring early intervention.
Updated on Oct. 5, 2026 in Babies
Live Poll
Should states prioritize funding universal newborn genetic screening despite high implementation costs?
New York implemented statewide newborn screening for metachromatic leukodystrophy in September 2025. This move made the state one of three nationwide to perform standard testing for the rare genetic disorder.
Why it matters
Newborn screening programs add conditions to their panels when effective treatments become available, though many states delay implementation due to high startup costs. Federal funding proposals seek to offset these expenses to improve early detection.
New York currently tests newborns for 50 different diseases. Only three states in the U.S. currently include metachromatic leukodystrophy as a standard part of their newborn screening panels.
The players
U.S. Department of Health and Human Services
This federal agency oversees national health policy, including the coordination of newborn screening review committees.
Recommended Uniform Screening Panel
This federal advisory body determines the list of conditions that states are recommended to include in their universal newborn screening programs.
The details
Newborn screening involves testing blood samples obtained via heel pricks shortly after birth to identify genetic conditions. New York has funded its current testing protocol through federal grants following the FDA approval of gene therapy for the disorder in 2024.
Timeline
New York began newborn screening for PKU in 1965.
New York launched metachromatic leukodystrophy screening in September 2025.
The federal panel added metachromatic leukodystrophy in December 2025.
A federal bill to fund screening was introduced on September 24, 2026.
New York's current federal grant funding is scheduled to expire in September 2027.
Culture Shift
The expansion of state screening panels reflects a broader shift toward integrating gene therapy milestones into public health policy. This movement prioritizes early detection to leverage new treatments, moving away from reactive medical care toward proactive genetic management.
New parents in the state can expect their newborns to be screened for metachromatic leukodystrophy as part of the standard blood test performed after birth. This testing provides critical information that allows for early intervention if a genetic condition is identified.
The takeaway
Early screening is essential for managing rare genetic disorders that have newly developed treatment options. Families should consult with their pediatricians to understand the full panel of tests administered to newborns in their state.
Further reading
Learn more about infant health programs on our Babies page.
Source note: This article includes information reported by Newsday.
Live Poll
Should states prioritize funding universal newborn genetic screening despite high implementation costs?
